Current Report Filing (8-k)
July 19 2021 - 4:07PM
Edgar (US Regulatory)
0000887247
false
0000887247
2021-07-16
2021-07-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
July 16, 2021
ADAMIS PHARMACEUTICALS CORPORATION
(Exact Name of Registrant as Specified in Charter)
Delaware
|
|
0-26372
|
|
82-0429727
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
11682 El Camino Real, Suite 300
San Diego, CA
|
|
92130
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (858) 997-2400
(Former name or Former Address, if Changed Since
Last Report.)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of
the Exchange Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on
which registered
|
Common Stock
|
|
ADMP
|
|
NASDAQ Capital Market
|
Indicate by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
|
Emerging growth company ☐
|
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
|
Item 5.07
|
Submission of Matters to a Vote of Security Holders.
|
At the annual meeting of stockholders of Adamis
Pharmaceuticals Corporation (the “Company”) held virtually on July 16, 2021 (the “Meeting”), stockholders holding
and entitled to vote 74,873,343 shares of common stock of the Company, or approximately 50.29% of the outstanding shares on the record
date for the Meeting, were present either by attendance via live webcast or by proxy. At the Meeting, the Company’s stockholders
voted on the proposals below, which are described in more detail in the Company’s definitive proxy statement for the Meeting that
was filed with the U.S. Securities and Exchange Commission on June 14, 2021 (the “Proxy Statement”).
At the Meeting, stockholders:
(1) elected Howard C. Birndorf, Roshawn
A. Blunt, Dennis J. Carlo, Ph.D., David J. Marguglio, and Richard C. Williams as directors to hold office until the 2022 Annual Meeting
of Stockholders, or until such person’s successor is duly elected and qualified, or until such person’s earlier resignation,
death, or removal;
(2) approved, on an advisory basis, the compensation
paid to our named executive officers as disclosed in the Proxy Statement; and
(3) ratified the appointment of BDO USA,
LLP, as our independent registered public accounting firm for the fiscal year ending December 31, 2021.
The following sets forth detailed information
regarding the final results of the voting on the proposals at the Meeting:
1. Election
of the five nominees to the board of directors:
|
Votes For
|
Votes Withheld
|
Broker Non-Votes
|
Howard C. Birndorf
|
28,543,221
|
9,027,328
|
37,302,794
|
Roshawn A. Blunt
|
28,869,605
|
8,700,944
|
37,302,794
|
Dennis J. Carlo, Ph.D.
|
29,929,637
|
7,640,912
|
37,302,794
|
David J. Marguglio
|
31,524,893
|
6,045,656
|
37,302,794
|
Richard C. Williams
|
28,618,406
|
8,953,143
|
37,302,794
|
2. Approval,
on a nonbinding advisory basis, of the compensation of the Company’s named executive officers:
Votes For
|
Votes Against
|
Votes Abstaining
|
Broker Non-Votes
|
17,821,561
|
17,812,097
|
1,936,891
|
37,302,794
|
3. Ratification of the selection of BDO USA, LLP, as independent registered public accounting firm for the year ending December 31, 2021:
Votes For
|
Votes Against
|
Votes Abstaining
|
Broker Non-Votes
|
65,882,702
|
3,326,893
|
5,663,748
|
0
|
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ADAMIS PHARMACEUTICALS CORPORATION
|
|
|
|
|
|
|
|
|
|
Dated: July 19, 2021
|
By:
|
/s/ Robert O. Hopkins
|
|
Name:
|
Robert O. Hopkins
|
|
Title:
|
Chief Financial Officer
|
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Sep 2023 to Sep 2024